Publications by authors named "B P Gloor"
Article Synopsis
- Researchers wanted to see if a new method called fully closed-loop (FCL) glucose control is better and safer than the usual way (UC) for managing high blood sugar in surgery patients.
- In a study with 37 patients, those using FCL spent more time in a healthy blood sugar range (80.1%) compared to those using UC (53.7%).
- The FCL method helped control high blood sugar without causing low blood sugar, proving to be a safe and effective way for patients during and after surgery.
Article Synopsis
- The study investigates the differences between high-immunogenic (HI-PDAC) and low-immunogenic (LI-PDAC) pancreatic ductal adenocarcinoma (PDAC) tumors, focusing on how the immune environment affects their responses to treatments.
- Using spatial proteomic and transcriptomic analyses from 220 PDAC patients, researchers discovered that HI-PDAC tumors have more immune-active environments with higher levels of T-cells and immune-related markers compared to LI-PDAC tumors, which display immune evasion.
- The findings suggest that HI-PDAC patients tend to have better outcomes but also show signs of immune exhaustion, indicating that understanding these immune dynamics could help improve treatment strategies for PDAC, particularly with immune checkpoint therapies.
Background: Combination of immunotherapy and chemotherapy is recommended for first line treatment of gastric adenocarcinoma (GC) patients with locally advanced unresectable disease or metastatic disease. However, data regarding the concordance rate between PD-L1 combined positive score (CPS) in primary GC and matched regional lymph node metastasis (LNmet) or matched distant metastasis (Dmet) is limited.
Methods: Tissue microarray sections from primary resected GC, LNmet and Dmet were immunohistochemically stained with anti-PD-L1 (clone SP263).
Background: Lymph node and resection margin status are associated with oncologic outcomes after pancreaticoduodenectomy for pancreatic ductal adenocarcinoma. However, surgical radicality at the portomesenteric axis in case of suspected infiltration remains controversial.
Methods: Clinicopathological data of patients who underwent a partial or total pancreaticoduodenectomy for PDAC between 2012 to 2019 in 2 major hepato-pancreato-biliary centers in Germany and Switzerland were assessed.
Objective: Most patients with pancreatic ductal adenocarcinoma (PDAC) will experience recurrence after resection. Here, we investigate spatially organised immune determinants of PDAC recurrence.
Design: PDACs (n=284; discovery cohort) were classified according to recurrence site as liver (n=93/33%), lung (n=49/17%), local (n=31/11%), peritoneal (n=38/13%) and no-recurrence (n=73/26%).